Chronic lymphocytic leukemia (CLL) cells have variably low surface IgM (sIgM) levels/signaling capacity, influenced by chronic antigen engagement at tissue sites. Within these low levels, CLL with relatively high sIgM (CLLhigh) progresses more rapidly than CLL with low sIgM (CLLlow). During ibrutinib therapy, surviving CLL cells redistribute into the peripheral blood and can recover sIgM expression. Return of CLL cells to tissue may eventually recur, where cells with high sIgM could promote tumor growth. We analyzed time to new treatment (TTNT) following ibrutinib in 70 patients with CLL (median follow-up of 66 months) and correlated it with pretreatment sIgM levels and signaling characteristics. Pretreatment sIgM levels correlated with signaling capacity, as measured by intracellular Ca2+ mobilization (iCa2+), in vitro (r = 0.70; P < .0001). High sIgM levels/signaling strongly correlated with short TTNT (P < .05), and 36% of patients with CLLhigh vs 8% of patients with CLLlow progressed to require a new treatment. In vitro, capacity of ibrutinib to inhibit sIgM-mediated signaling inversely correlated with pretherapy sIgM levels (r = -0.68; P = .01) or iCa2+ (r = -0.71; P = .009). In patients, sIgM-mediated iCa2+ and ERK phosphorylation levels were reduced by ibrutinib therapy but not abolished. The residual signaling capacity downstream of BTK was associated with high expression of sIgM, whereas it was minimal when sIgM expression was low (P < .05). These results suggested that high sIgM levels facilitated CLL cell resistance to ibrutinib in patients. The CLL cells, surviving in the periphery with high sIgM expression, include a dangerous fraction that is able to migrate to tissue and receive proliferative stimuli, which may require targeting by combined approaches.

Department of Haematology Azienda Ospedaliera di Cosenza Cosenza Italy

Department of Internal Medicine Hematology and Oncology University Hospital Brno and Faculty of Medicine Masaryk University Brno Czech Republic

Department of Molecular Medicine and Surgery Karolinska Institutet Stockholm Sweden; and

Haematology Department Cancer Care Directorate University Hospital Southampton NHS Trust Southampton United Kingdom

Molecular Medicine CEITEC Masaryk University Brno Czech Republic

School of Cancer Sciences Cancer Research UK and NIHR Experimental Cancer Medicine Centres Faculty of Medicine University of Southampton Southampton United Kingdom

Strategic Research Program on CLL and B cell Neoplasia Unit Experimental Oncology Università Vita Salute San Raffaele and IRCCS Ospedale San Raffaele Milan Italy

T Cypher Bio Oxford United Kingdom

The Francis Crick Institute London United Kingdom

Zobrazit více v PubMed

Lam KP, Kühn R, Rajewsky K. In vivo ablation of surface immunoglobulin on mature B cells by inducible gene targeting results in rapid cell death. Cell. 1997;90(6):1073-1083. PubMed

Forconi F, Lanham SA, Chiodin G. Biological and clinical insight from analysis of the tumor b-cell receptor structure and function in chronic lymphocytic leukemia. Cancers (Basel). 2022;14(3):663. PubMed PMC

Stevenson FK, Forconi F, Kipps TJ. Exploring the pathways to chronic lymphocytic leukemia. Blood. 2021;138(10):827-835. PubMed PMC

Packham G, Krysov S, Allen A, et al. . The outcome of B-cell receptor signaling in chronic lymphocytic leukemia: proliferation or anergy. Haematologica. 2014;99(7):1138-1148. PubMed PMC

Byrd JC, Furman RR, Coutre SE, et al. . Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med. 2013;369(1):32-42. PubMed PMC

Burger JA. Inhibiting B-cell receptor signaling pathways in chronic lymphocytic leukemia. Curr Hematol Malig Rep. 2012;7(1):26-33. PubMed

Woyach JA, Bojnik E, Ruppert AS, et al. . Bruton’s tyrosine kinase (BTK) function is important to the development and expansion of chronic lymphocytic leukemia (CLL). Blood. 2014;123:1207-1213. PubMed PMC

Byrd JC, O’Brien S, James DF. Ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med. 2013;369(13):1278-1279. PubMed

Ternynck T, Dighiero G, Follezou J, Binet JL. Comparison of normal and CLL lymphocyte surface Ig determinants using peroxidase-labeled antibodies. I. Detection and quantitation of light chain determinants. Blood. 1974;43(6):789-795. PubMed

Mockridge CI, Potter KN, Wheatley I, Neville LA, Packham G, Stevenson FK. Reversible anergy of sIgM-mediated signaling in the two subsets of CLL defined by VH-gene mutational status. Blood. 2007;109(10):4424-4431. PubMed

Lanham S, Hamblin T, Oscier D, Ibbotson R, Stevenson F, Packham G. Differential signaling via surface IgM is associated with VH gene mutational status and CD38 expression in chronic lymphocytic leukemia. Blood. 2003;101(3):1087-1093. PubMed

Seifert M, Sellmann L, Bloehdorn J, et al. . Cellular origin and pathophysiology of chronic lymphocytic leukemia. J Exp Med. 2012;209(12):2183-2198. PubMed PMC

Forconi F, Potter KN, Wheatley I, et al. . The normal IGHV1-69-derived B-cell repertoire contains stereotypic patterns characteristic of unmutated CLL. Blood. 2010;115(1):71-77. PubMed

Stevenson FK, Sahota SS, Ottensmeier CH, Zhu D, Forconi F, Hamblin TJ. The occurrence and significance of V gene mutations in B cell-derived human malignancy. Adv Cancer Res. 2001;83:81-116. PubMed

Damle RN, Wasil T, Fais F, et al. . Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood. 1999;94(6):1840-1847. PubMed

Hamblin TJ, Davis Z, Gardiner A, Oscier DG, Stevenson FK. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood. 1999;94(6):1848-1854. PubMed

D’Avola A, Drennan S, Tracy I, et al. . Surface IgM expression and function are associated with clinical behavior, genetic abnormalities, and DNA methylation in CLL. Blood. 2016;128(6):816-826. PubMed

Herman SE, Gordon AL, Hertlein E, et al. . Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. Blood. 2011;117(23):6287-6296. PubMed PMC

Honigberg LA, Smith AM, Sirisawad M, et al. . The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc Natl Acad Sci USA. 2010;107(29):13075-13080. PubMed PMC

Chen SS, Chang BY, Chang S, et al. . BTK inhibition results in impaired CXCR4 chemokine receptor surface expression, signaling and function in chronic lymphocytic leukemia. Leukemia. 2016;30(4):833-843. PubMed PMC

de Rooij MF, Kuil A, Geest CR, et al. . The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia. Blood. 2012;119(11):2590-2594. PubMed

Wodarz D, Garg N, Komarova NL, et al. . Kinetics of CLL cells in tissues and blood during therapy with the BTK inhibitor ibrutinib. Blood. 2014; 123(26):4132-4135. PubMed PMC

Herman SE, Niemann CU, Farooqui M, et al. . Ibrutinib-induced lymphocytosis in patients with chronic lymphocytic leukemia: correlative analyses from a phase II study. Leukemia. 2014;28(11):2188-2196. PubMed PMC

Drennan S, Chiodin G, D’Avola A, et al. . Ibrutinib therapy releases leukemic surface IgM from antigen drive in chronic lymphocytic leukemia patients. Clin Cancer Res. 2019;25(8):2503-2512. PubMed

Jain P, Keating M, Wierda W, et al. . Outcomes of patients with chronic lymphocytic leukemia (CLL) after discontinuing ibrutinib. Blood. 2015; 125(13):2062-2067. PubMed PMC

Advani RH, Buggy JJ, Sharman JP, et al. . Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. J Clin Oncol. 2013;31(1):88-94. PubMed PMC

Maddocks KJ, Ruppert AS, Lozanski G, et al. . Etiology of ibrutinib therapy discontinuation and outcomes in patients with chronic lymphocytic leukemia. JAMA Oncol. 2015;1(1):80-87. PubMed PMC

Forum UC. Ibrutinib for relapsed/refractory CLL: a UK and Ireland analysis of outcomes in 315 patients. Haematologica. 2016; 101(12): 1563-1572. PubMed PMC

Liu TM, Woyach JA, Zhong Y, et al. . Hypermorphic mutation of phospholipase C, γ2 acquired in ibrutinib-resistant CLL confers BTK independency upon B-cell receptor activation. Blood. 2015;126(1):61-68. PubMed PMC

Woyach JA, Furman RR, Liu TM, et al. . Resistance mechanisms for the Bruton’s tyrosine kinase inhibitor ibrutinib. N Engl J Med. 2014;370(24):2286-2294. PubMed PMC

Burger JA, Landau DA, Taylor-Weiner A, et al. . Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition. Nat Commun. 2016;7(1):11589. PubMed PMC

Sharma S, Galanina N, Guo A, et al. . Identification of a structurally novel BTK mutation that drives ibrutinib resistance in CLL. Oncotarget. 2016; 7(42):68833-68841. PubMed PMC

Ahn IE, Underbayev C, Albitar A, et al. . Clonal evolution leading to ibrutinib resistance in chronic lymphocytic leukemia. Blood. 2017;129(11): 1469-1479. PubMed PMC

Woyach JA, Ruppert AS, Guinn D, et al. . BTKC481S-mediated resistance to ibrutinib in chronic lymphocytic leukemia. J Clin Oncol. 2017;35(13):1437-1443. PubMed PMC

Kadri S, Lee J, Fitzpatrick C, et al. . Clonal evolution underlying leukemia progression and Richter transformation in patients with ibrutinib-relapsed CLL. Blood Adv. 2017;1(12):715-727. PubMed PMC

Quinquenel A, Fornecker LM, Letestu R, et al. ; French Innovative Leukemia Organization (FILO) CLL Group . Prevalence of BTK and PLCG2 mutations in a real-life CLL cohort still on ibrutinib after 3 years: a FILO group study. Blood. 2019;134(7):641-644. PubMed

Gángó A, Alpár D, Galik B, et al. . Dissection of subclonal evolution by temporal mutation profiling in chronic lymphocytic leukemia patients treated with ibrutinib. Int J Cancer. 2020;146(1):85-93. PubMed

Sedlarikova L, Petrackova A, Papajik T, Turcsanyi P, Kriegova E. Resistance-associated mutations in chronic lymphocytic leukemia patients treated with novel agents. Front Oncol. 2020;10:894. PubMed PMC

Hallek M, Cheson BD, Catovsky D, et al. . iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood. 2018;131(25):2745-2760. PubMed

Forconi F, Sahota SS, Raspadori D, Mockridge CI, Lauria F, Stevenson FK. Tumor cells of hairy cell leukemia express multiple clonally related immunoglobulin isotypes via RNA splicing. Blood. 2001;98(4):1174-1181. PubMed

Rossi D, Sozzi E, Puma A, et al. . The prognosis of clinical monoclonal B cell lymphocytosis differs from prognosis of Rai 0 chronic lymphocytic leukaemia and is recapitulated by biological risk factors. Br J Haematol. 2009;146(1):64-75. PubMed

Döhner H, Stilgenbauer S, Benner A, et al. . Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med. 2000;343(26): 1910-1916. PubMed

Tissino E, Benedetti D, Herman SEM, et al. . Functional and clinical relevance of VLA-4 (CD49d/CD29) in ibrutinib-treated chronic lymphocytic leukemia. J Exp Med. 2018;215(2):681-697. PubMed PMC

Robinson JT, Thorvaldsdóttir H, Winckler W, et al. . . Integrative genomics viewer. Nat Biotechnol. 2011;29(1):24-26. PubMed PMC

Herman SEM, Montraveta A, Niemann CU, et al. . The Bruton tyrosine kinase (BTK) inhibitor acalabrutinib demonstrates potent on-target effects and efficacy in two mouse models of chronic lymphocytic leukemia. Clin Cancer Res. 2017;23(11):2831-2841. PubMed PMC

Srinivasan L, Sasaki Y, Calado DP, et al. . PI3 kinase signals BCR-dependent mature B cell survival. Cell. 2009;139(3):573-586. PubMed PMC

Fluckiger AC, Li Z, Kato RM, et al. . Btk/Tec kinases regulate sustained increases in intracellular Ca2+ following B-cell receptor activation. EMBO J. 1998;17(7):1973-1985. PubMed PMC

Buhl AM, Cambier JC. Phosphorylation of CD19 Y484 and Y515, and linked activation of phosphatidylinositol 3-kinase, are required for B cell antigen receptor-mediated activation of Bruton’s tyrosine kinase. J Immunol. 1999;162(8):4438-4446. PubMed

Bojarczuk K, Sasi BK, Gobessi S, et al. . BCR signaling inhibitors differ in their ability to overcome Mcl-1-mediated resistance of CLL B cells to ABT-199. Blood. 2016;127(25):3192-3201. PubMed

Baudot AD, Jeandel PY, Mouska X, et al. . The tyrosine kinase Syk regulates the survival of chronic lymphocytic leukemia B cells through PKCdelta and proteasome-dependent regulation of Mcl-1 expression. Oncogene. 2009;28(37):3261-3273. PubMed

Gobessi S, Laurenti L, Longo PG, et al. . Inhibition of constitutive and BCR-induced Syk activation downregulates Mcl-1 and induces apoptosis in chronic lymphocytic leukemia B cells. Leukemia. 2009;23(4):686-697. PubMed

Sinha S, Boysen JC, Chaffee KG, et al. . Chronic lymphocytic leukemia cells from ibrutinib treated patients are sensitive to Axl receptor tyrosine kinase inhibitor therapy. Oncotarget. 2018;9(98):37173-37184. PubMed PMC

Seda V, Vojackova E, Ondrisova L, et al. . FoxO1-GAB1 axis regulates homing capacity and tonic AKT activity in chronic lymphocytic leukemia. Blood. 2021;138(9):758-772. PubMed PMC

Cosimo E, Tarafdar A, Moles MW, et al. . AKT/mTORC2 inhibition activates FOXO1 function in CLL cells reducing B-cell receptor-mediated survival. Clin Cancer Res. 2019;25(5):1574-1587. PubMed PMC

Longo PG, Laurenti L, Gobessi S, Sica S, Leone G, Efremov DG. The Akt/Mcl-1 pathway plays a prominent role in mediating antiapoptotic signals downstream of the B-cell receptor in chronic lymphocytic leukemia B cells. Blood. 2008;111(2):846-855. PubMed

Longo PG, Laurenti L, Gobessi S, et al. . The Akt signaling pathway determines the different proliferative capacity of chronic lymphocytic leukemia B-cells from patients with progressive and stable disease. Leukemia. 2007;21(1):110-120. PubMed

Hu N, Wang F, Sun T, et al. . Follicular lymphoma-associated BTK mutations are inactivating resulting in augmented AKT activation. Clin Cancer Res. 2021;27(8):2301-2313. PubMed PMC

Coelho V, Krysov S, Steele A, et al. . Identification in CLL of circulating intraclonal subgroups with varying B-cell receptor expression and function. Blood. 2013;122(15):2664-2672. PubMed

FoxO1/Rictor axis induces a nongenetic adaptation to ibrutinib via Akt activation in chronic lymphocytic leukemia